Curative efficacy for nasal type extranodal NK/T-cell lymphoma by autologous peripheral blood stem cell transplantation after sequencing chemotherapy and radiotherapy.
10.7534/j.issn.1009-2137.2013.06.020
- Author:
Cun-Bang WANG
1
;
Hai BAI
2
;
Rui XI
1
;
Yao-Zhu PAN
1
;
Shu-Fen XU
1
;
Qian ZHANG
1
;
Yan CHEN
1
;
Jin-Mao ZHOU
1
Author Information
1. Department of Hematology, Lanzhou General Hospital of Lanzhou Military Command, Hematological Center of Chinese PLA, Lanzhou 730050, Gansu Province, China.
2. Department of Hematology, Lanzhou General Hospital of Lanzhou Military Command, Hematological Center of Chinese PLA, Lanzhou 730050, Gansu Province, China. E-mail: baihai98@tom.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Antineoplastic Combined Chemotherapy Protocols;
administration & dosage;
therapeutic use;
Combined Modality Therapy;
Female;
Humans;
Lymphoma, Extranodal NK-T-Cell;
therapy;
Male;
Middle Aged;
Peripheral Blood Stem Cell Transplantation;
Transplantation Conditioning;
Transplantation, Autologous;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(6):1477-1481
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to explore the curative efficacy for nasal type extranodal NK/T-cell lymphoma by autologous peripheral blood stem cell transplantation (APBSCT) after sequencing chemotherapy and radiotherapy. A total 65 cases diagnosed as nasal type extranodal NK/T-cell lymphoma by pathology and immuno-histochemistry were treated with chemotherapy and radiotherapy in our hospital from January of 2000 to December of 2009. They were divided into observation group (34 cases) and transplantation group (31 cases). The 34 cases of observation group were ceased from treatment, the 31 cases in transplantation group received APBSCT after conditioning regimen with TBI combined VEMAC. Autologous peripheral blood stem cells were mobilized with chemotherapy combined rhG-CSF. The patients were followed up for 3-5 years. The results showed that some side-effects such as bone marrow suppression and injure of oral cavity mucosa were found in patients after sequencing chemotherapy and radiotherapy. All patients in transplantation group obtained hematopoietic reconstruction, and there were no any special side effect such as VOD. In transplantation group, the median time of ANC ≥ 0.5×10(9)/L was 14 (11-17) days, median time of WBC count ≥ 4.0×10(9)/L was 17 (16-20) days, median time of Plt count ≥ 50×10(8)/L were 25 (23-28) days. After chemotherapy and radiotherapy, effective rate of treatment was 91.2% in observation group, whereas was 90.3% in transplantation group, there were no obvious difference between two groups (P > 0.05). After following up about 1 year, effective rate of treatment was 76.5% in observation group, whereas was 96.8% in transplantation group, there were obvious difference between two groups (P < 0.05). After following up about 3 years and 5 years the disease-free survival (DFS) was 61.3%, 43.5% and 87.1%, 81.5% in observation group and transplantation group, there was significant difference between two groups (P < 0.05). It is concluded that treatment with APBSCT after sequencing chemotherapy and radiotherapy for nasal type extranodal NK/T-cell lymphoma may increase DFS efficiently.
